We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Register to vote Register by 18 June to vote in the General Election on 4 July.
The symptoms and epidemiology of botulism.
Guidance for people who have been diagnosed with a mpox infection and who have been advised to self-isolate at home.
Public health principles to support planning for events and mass gatherings during the current mpox outbreak.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine etrasimod (Velsipity) to treat people with moderately to severely active ulcerative colitis.
The mycology reference laboratory (MRL) provides a comprehensive laboratory service for the diagnosis and management of fungal infections.
Information on the status of mpox as a high consequence infectious disease (HCID).
Advice and guidance on the health needs of migrant patients for healthcare practitioners.
To better understand Mpox and its spread within the UK, VDEC developed an immunoassay to assess immune responses to Mpox infection and new vaccines.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (9 April 2024) approved the medicine fosdenopterin (Nulibry) to treat the genetic disease Molybdenum Cofactor Deficiency (MoCD) Type A
Advice and guidance on the health needs of migrant patients from Lesotho for healthcare practitioners.
Measles immunisation information for public health professionals, including updates.
FCDO travel advice for Lesotho. Includes safety and security, insurance, entry requirements and legal differences.
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (30 January 2024) approved the medicine momelotinib (Omjjara) to treat the symptoms experienced by adult myelofibrosis patients who have moderate or severe anaemia (a low number of red blood cells...
The purpose of this leaflet is to give an update on progress with the Risk Sharing Scheme for Disease Modifying Therapies (DMTs) in Multiple Sclerosis.
Patients with severe alopecia areata (patchy hair loss) could access a new medicine to help treat their condition.
UK Health Security Agency proficiency testing (PT) samples for food and water microbiology in Lenticule® disc format.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).